Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0AXTQT |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | CD33-11A1-v1417-kK183C-hGl |
|||||
| Synonyms |
CD33-11A1-v1417-kK183C-hGl
Click to Show/Hide
|
|||||
| Antigen Name | Myeloid cell surface antigen CD33 (CD33) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CD33-11A1-v1417- kK183C-hGl-LP2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.18 ng/ml
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA | NB4 cells | CVCL_0005 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.55 ng/ml
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation | HL60 cells | CVCL_0002 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
6.68 ng/ml
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Acute erythroid leukemia, Erythroleukemia | HEL92.1.7 cells | CVCL_2481 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
9.31 ng/ml
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Esophageal squamous cell carcinoma | TF-1 cells | CVCL_1759 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
706 ng/ml
|
Negative CD33 expression (CD33-) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
CD33-11A1-v1417- kK183C-hGl-LP48 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.69 ng/ml
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA | NB4 cells | CVCL_0005 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1 ng/ml
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation | HL60 cells | CVCL_0002 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
5.06 ng/ml
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Acute erythroid leukemia, Erythroleukemia | HEL92.1.7 cells | CVCL_2481 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
31.2 ng/ml
|
Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Esophageal squamous cell carcinoma | TF-1 cells | CVCL_1759 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1340 ng/ml
|
Negative CD33 expression (CD33-) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||